Literature DB >> 25762791

Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies.

Diego A Espinosa1, Gabriel M Gutierrez2, Maricarmen Rojas-López1, Amy R Noe2, Lirong Shi1, Sze-Wah Tse1, Photini Sinnis1, Fidel Zavala1.   

Abstract

Studies in animals and human volunteers demonstrate that antibodies against the repeat-region of the Plasmodium circumsporozoite protein (CSP) abrogate sporozoite infection. However, the realization that the N- and C- terminal regions flanking the repeats play essential roles in parasite infectivity raised the possibility that they could be targeted by protective antibodies. We characterized a monoclonal antibody (mAb5D5) specific for the N-terminus of the P. falciparum CSP, which inhibits the proteolytic cleavage of the CSP, a key requirement for parasite infection of hepatocytes. Adoptive transfer of mAb5D5 strongly inhibits the in vivo infection of sporozoites expressing the N-terminus of P. falciparum CSP, and this protection is greatly enhanced when combined with antirepeat antibodies. Our results show that antibodies interfering with molecular processes required for parasite infectivity can exert a strong in vivo protective activity and indicate that pre-erythrocytic vaccines against Plasmodium should include the CSP N-terminal region.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CSP; P. falciparum; antibodies; malaria; sporozoites; vaccine

Mesh:

Substances:

Year:  2015        PMID: 25762791      PMCID: PMC4559189          DOI: 10.1093/infdis/jiv154

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Binding and invasion of liver cells by Plasmodium falciparum sporozoites. Essential involvement of the amino terminus of circumsporozoite protein.

Authors:  Dharmendar Rathore; John B Sacci; Patricia de la Vega; Thomas F McCutchan
Journal:  J Biol Chem       Date:  2001-12-20       Impact factor: 5.157

2.  Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein.

Authors:  M A Roggero; B Filippi; P Church; S L Hoffman; U Blum-Tirouvanziam; J A Lopez; F Esposito; H Matile; C D Reymond; N Fasel
Journal:  Mol Immunol       Date:  1995-12       Impact factor: 4.407

3.  Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein.

Authors:  Cathrine Persson; Giane A Oliveira; Ali A Sultan; Purnima Bhanot; Victor Nussenzweig; Elizabeth Nardin
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

4.  Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria.

Authors:  F Zavala; J P Tam; M R Hollingdale; A H Cochrane; I Quakyi; R S Nussenzweig; V Nussenzweig
Journal:  Science       Date:  1985-06-21       Impact factor: 47.728

5.  Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR.

Authors:  O Bruña-Romero; J C Hafalla; G González-Aseguinolaza; G Sano; M Tsuji; F Zavala
Journal:  Int J Parasitol       Date:  2001-11       Impact factor: 3.981

6.  Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite.

Authors:  N Yoshida; R S Nussenzweig; P Potocnjak; V Nussenzweig; M Aikawa
Journal:  Science       Date:  1980-01-04       Impact factor: 47.728

7.  Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria.

Authors:  P Romero; J L Maryanski; G Corradin; R S Nussenzweig; V Nussenzweig; F Zavala
Journal:  Nature       Date:  1989-09-28       Impact factor: 49.962

8.  Gene targeting in malaria parasites.

Authors:  R Ménard; C Janse
Journal:  Methods       Date:  1997-10       Impact factor: 3.608

9.  Synthetic peptide vaccine confers protection against murine malaria.

Authors:  F Zavala; J P Tam; P J Barr; P J Romero; V Ley; R S Nussenzweig; V Nussenzweig
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

10.  The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion.

Authors:  Alida Coppi; Consuelo Pinzon-Ortiz; Christina Hutter; Photini Sinnis
Journal:  J Exp Med       Date:  2005-01-03       Impact factor: 14.307

View more
  46 in total

Review 1.  Plasmodium Sporozoite Biology.

Authors:  Friedrich Frischknecht; Kai Matuschewski
Journal:  Cold Spring Harb Perspect Med       Date:  2017-05-01       Impact factor: 6.915

Review 2.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

3.  A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver.

Authors:  Lawrence T Wang; Lais S Pereira; Yevel Flores-Garcia; James O'Connor; Barbara J Flynn; Arne Schön; Nicholas K Hurlburt; Marlon Dillon; Annie S P Yang; Amanda Fabra-García; Azza H Idris; Bryan T Mayer; Monica W Gerber; Raphael Gottardo; Rosemarie D Mason; Nicole Cavett; Reid B Ballard; Neville K Kisalu; Alvaro Molina-Cruz; Jorgen Nelson; Rachel Vistein; Carolina Barillas-Mury; Rogerio Amino; David Baker; Neil P King; Robert W Sauerwein; Marie Pancera; Ian A Cockburn; Fidel Zavala; Joseph R Francica; Robert A Seder
Journal:  Immunity       Date:  2020-09-17       Impact factor: 31.745

Review 4.  Vaccines to Accelerate Malaria Elimination and Eventual Eradication.

Authors:  Julie Healer; Alan F Cowman; David C Kaslow; Ashley J Birkett
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

5.  A Prime/Boost PfCS14KM/MVA-sPfCSM Vaccination Protocol Generates Robust CD8+ T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria.

Authors:  Aneesh Vijayan; Ernesto Mejías-Pérez; Diego A Espinosa; Suresh C Raman; Carlos Oscar S Sorzano; Fidel Zavala; Mariano Esteban
Journal:  Clin Vaccine Immunol       Date:  2017-05-05

6.  Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains.

Authors:  Raul Herrera; Charles Anderson; Krishan Kumar; Alvaro Molina-Cruz; Vu Nguyen; Martin Burkhardt; Karine Reiter; Richard Shimp; Randall F Howard; Prakash Srinivasan; Michael J Nold; Daniel Ragheb; Lirong Shi; Mark DeCotiis; Joan Aebig; Lynn Lambert; Kelly M Rausch; Olga Muratova; Albert Jin; Steven G Reed; Photini Sinnis; Carolina Barillas-Mury; Patrick E Duffy; Nicholas J MacDonald; David L Narum
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

Review 7.  Immune Responses in Malaria.

Authors:  Carole A Long; Fidel Zavala
Journal:  Cold Spring Harb Perspect Med       Date:  2017-08-01       Impact factor: 6.915

8.  Circumsporozoite protein as a potential target for antimalarials.

Authors:  Cristina Fernández-Arias; Sara Mashoof; Jing Huang; Moriya Tsuji
Journal:  Expert Rev Anti Infect Ther       Date:  2015-06-16       Impact factor: 5.091

Review 9.  Antibodies against Plasmodium falciparum malaria at the molecular level.

Authors:  Jean-Philippe Julien; Hedda Wardemann
Journal:  Nat Rev Immunol       Date:  2019-08-28       Impact factor: 53.106

10.  Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.

Authors:  DeAnna J Friedman-Klabanoff; Andrea A Berry; Mark A Travassos; Catherine Cox; Yingjun Zhou; Annie X Mo; Effie Y H Nomicos; Gregory A Deye; Marcela F Pasetti; Matthew B Laurens
Journal:  Vaccine       Date:  2021-01-22       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.